Dec 19 (Reuters) - The U.S. Food and Drug Administration said on Friday it has authorized the marketing of six Altria-owned on! PLUS nicotine pouch products, through a pilot program aimed to fast-track reviews of such products.
The authorization was the first under the pilot program that the FDA launched in September, and applies to six on! PLUS nicotine pouches, which are manufactured by Helix Innovations LLC, an Altria joint venture for the global on! PLUS nicotine pouch portfolio.
The company had applied for premarket authorization for the products in June 2024.
The decision allows the mint, tobacco and wintergreen-flavored pouches, offered in 6 mg and 9 mg nicotine strengths, to be legally sold to adults in the United States.
The FDA said its decision was based on evidence that the products contain lower levels of harmful chemicals, posing a lower risk of cancer and other serious health conditions compared to other smokeless tobacco products. The authorization applies only to the specified products and not to other Helix offerings.
Nicotine pouches, which users insert under the lip, are the fastest-growing category of tobacco products in the U.S., and are generally considered among the lowest-risk smoking alternatives given they do not involve inhalation and do not contain tobacco.
Earlier this year, 20 Zyn products, owned by Philip Morris became the first in the nicotine pouch category to receive market authorization from the FDA in the U.S.
Zyn products were approved in January, more than five years after the company first submitted its application.
Tobacco companies have invested heavily in developing and marketing alternatives to cigarettes as demand for these products grows.
"on! PLUS will resume taking new orders for retail accounts in Florida, North Carolina and Texas and on e-commerce soon," Altria said to Reuters.
Nicotine in adolescence can harm the parts of the brain that control attention, learning, mood and impulse control, according to the U.S. Centers for Disease Control and Prevention.
(Reporting by Sanskriti Shekhar and Juveria Tabassum in Bengaluru; Editing by Alan Barona)
LATEST POSTS
- 1
Without evidence, CDC changes messaging on vaccines and autism - 2Most loved Specially prepared Espresso Mix: Which Meal Do You Adore the Most?
- 321 Things You Ought to Never Tell Your Childless Companion
- 4Newly identified species of Tanzanian tree toad leapfrog the tadpole stage and give birth to toadlets
- 510 Natural products to Remember for Your Eating routine for a Better You
- Step by step instructions to Protect Your Senior Condo for Ideal Wellbeing and Solace
- Florence's Uffizi Gallery moves treasures to safety after cyberattack
- Flourishing in a Cutthroat Work Market: Vocation Methodologies
- Doulas play essential roles in reproductive health care – and more states are beginning to recognize it
- More than 3 million eye drops have been recalled from CVS, Walgreens and other national retailers. How to check if yours are safe
- Recent studies prove the ancient practice of nasal irrigation is effective at fighting the common cold
- The Solution to Individual budget: Dominating Cash The board
- Iran-backed militias reassert power in Iraq, proving the Islamic axis is still standing
- Comet MAPS faces a make-or-break moment as it dives toward the sun on April 4 — could it shine in the daytime sky?
